**EXHIBIT      10.38.1**

**CONFIDENTIAL        TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF**

**THIS        DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY**

**FILED        WITH THE COMMISSION.*****

**COLLABORATION        AGREEMENT**

**THIS        COLLABORATION AGREEMENT**
**Agreement**
**Effective        Date**
**King**
**Inyx**

**WHEREAS**

**WHEREAS**

**WHEREAS**

**NOW**
**        THEREFORE**

| **1.** | **DEFINITIONS** |
|--------|-----------------|

|   | **1.1** | **Definitions.**In                  addition to the terms defined elsewhere herein, as used in this                  Agreement,                  the following terms have the meanings specified below when used                  in this                  Agreement: |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**AAA**

**Act**

**Affiliate(s)**

**CONFIDENTIAL            TREATMENT**

----

**Agreement**

**Alliance        Management Committee**
**AMC**

**Approved        New Product**

**Assignors**

**Audited        Party**

**Auditing        Party**

**Calendar        Quarter**

**Calendar        Year**

**Change        of Control**

**Change        of Control Notice**

**COGS**

**CONFIDENTIAL            TREATMENT**

----

**Collaboration        Costs**

**Collaboration        Documents**

**Collaboration        Program**

**Competitor        Product**

**Confidential        Information**

**Consultant**

**CONFIDENTIAL            TREATMENT**

----

**Development        Agreement**

**Discretionary        Funding**

**Effective        Date**

**Excluded        New Product**

**Excluded        New Product Costs**

**Excluded        Patent Costs**

**FDA**

**GAAP**

**Improvement(s)**

**IND**

**indemnitee**

**indemnitor**

**Infringement**

**Infringement        Notice**

**CONFIDENTIAL            TREATMENT**

----

**Intal**
**Intal        HFA**

**Inyx**

**Inyx        Respiratory Products**

**King**

**King        Respiratory Product**

**Manufacturing        and Supply Agreement**

**Manufacturing        Offer Notice**

**market**
**marketing**

**Marketing        and Promotion Agreement**

**Marketing        Costs**

**CONFIDENTIAL            TREATMENT**

----

**Marketing        Plan and Budget**

**NDA**

**Net        Sales**
*** ***

**New        Product**

**Offered        Product**

**CONFIDENTIAL            TREATMENT**

----

**Patent        Rights**

**Person**

**Personnel        Costs**

**Product(s)**

**Product        Offer Notice**

**Program        Plans**

**Quality        Agreement**

**Regulatory        and IP Costs**

**Regulatory        Approval**

**CONFIDENTIAL            TREATMENT**

----

**Regulatory        Authority**

**Regulatory        Filings**

**Requested        Party**

**Requesting        Party**

**Respiratory        Offer Notice**

**Technology**

**Technology        Transfer Agreement**

**Term**

**Terminated        Agreement**

**Territory**

**Third        Party**

**CONFIDENTIAL            TREATMENT**

----

**Tilade**
**Tilade        HFA**

**Trademark**

**1.2**
**Interpretation**

| **2.** | **ADMINISTRATION                    OF THE COLLABORATION** |
|--------|------------------------------------------------------------|

|   | **2.1** | **Establishment                  and Function of AMC**.                  Inyx and King will establish an alliance management committee (the                  “**Alliance                  Management Committee**”                  or “**AMC**”)                  within thirty (30) days of the Effective Date to plan, administer,                  and                  monitor the activities of the parties under the Collaboration Program,                  including all activities set forth in the Program Plans, if any.                  In                  particular, the AMC will review and approve, or recommend revisions                  to,                  any Program Plans, review and monitor the progress of the Collaboration                  Program, and recommend necessary adjustments to the Collaboration                  Program.                  In planning, administering, and monitoring the Collaboration Program,                  the                  AMC will allocate tasks and responsibilities, taking into account                  each                  party's respective specific capacities and expertise in order to                  avoid                  duplication and to enhance synergies, as well as comply with the                  requirements of this Agreement and the other Collaboration                  Documents. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **2.2** | **Membership                  of the AMC**.                  Each party will appoint three (3) representatives of such party                  to the                  AMC. One of King's senior representatives will chair the AMC, but                  such                  chair shall not have a casting or tie-breaking vote. Both parties                  will                  have the right from time to time to substitute individuals, on                  a permanent                  or temporary basis, for any of its previously designated members                  of the                  AMC. The members appointed by each party will be vested with appropriate                  decision-making authority and power by such party. Members of the                  AMC will                  be senior executives of the parties (or their Affiliates), respectively,                  and will not be outside consultants, independent contractors, or                  outside                  legal counsel, but such Persons are permitted to attend meetings                  of the                  AMC. Each party will bear its own costs associated with its participation                  on the AMC. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **2.3** | **Committees**.                  The AMC will have the right and power to appoint and delegate its                  responsibilities to committees as reasonably needed to accomplish                  its work                  and the composition and eligibility requirements for the same will                  be                  agreed by the members of the AMC. Such committees may include regulatory,                  clinical/development, sales and marketing, and manufacturing committees.                  Except as otherwise mandated by the AMC in its minutes, each committee                  established by the AMC will be governed by the rules and guidelines                  applicable to the AMC set forth in this Agreement. The AMC will                  set forth                  clearly each such committee's decision making responsibilities                  that have                  been delegated to it by the AMC. Any member of a committee may                  send a                  designee to observe a committee if such member is unable to attend,                  but                  such observer will not vote in such member's place unless given                  a written                  proxy from such member of the committee. Each party will have the                  right at                  any time to substitute individuals, on a permanent or temporary                  basis, for                  any of its previously designated representatives to any committee,                  by                  giving written notice thereof to the other party. If an issue to                  be                  addressed by a committee appears to fall within the oversight and                  administration of more than one committee, such committees will                  confer                  with each other to determine which committee will oversee and administer                  such issue. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **2.4** | **Responsibilities                  of the AMC**.                  The AMC will be solely responsible for making all decisions not                  specifically reserved to either party hereunder, including decisions                  with                  respect to the following matters: |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | the                  definition, review, approval, and amendment (not less than annually)                  of                  the Program Plans, if any, and all related strategy and objectives                  (but                  not the actual conduct of such                  plans); |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | definition,                  review, and approval of and changes to the strategy and objectives                  (but                  not the actual conduct) of the Collaboration                  Program; |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | management                  and allocation of resources of the Collaboration                  Program; |
|--------|-------|--------------------------------------------------------------------------------------------------------|

|   | (iv) | proposal                  of all budgets for the Collaboration Program, including as described                  in                  Article 3; |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (v) | review                  and approval of all agreements required or entered into in connection                  with                  the Collaboration Program, and any and all amendments thereto;                  and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (vi) | performance                  of such other functions as appropriate to further the purposes                  of this                  Agreement and the Collaboration Program as determined from time                  to time by                  the parties. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **2.5** | **AMC                  Meetings**.                  During the Term of this Agreement, the AMC will meet: (a) at                  least                  once each Calendar Quarter on a date and at a location to be agreed                  to by                  the AMC in advance, and (b) upon written notice by either                  party to                  the other that a meeting is required or requested, in which case                  a meeting                  will be held within thirty (30) calendar days of such notice on                  a date and                  at a location to be agreed to by the parties, or sooner if warranted                  by                  circumstances. Notice requesting a meeting will include adequate                  information describing the activity to be reviewed. Any meetings                  of the                  AMC may be held in person at a location to be agreed to by the                  parties, or                  by videoconference or teleconference. Other representatives of                  the parties                  may attend AMC meetings as participants. At least one week prior                  to any                  meeting of the AMC, each of the parties will provide the other                  party with                  a proposed agenda of the matters to be discussed at such meeting.                  The                  parties will agree, at the first meeting of the AMC, upon procedures                  for                  maintaining meeting minutes. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **2.6** | **Vote                  and Approval**.                  The AMC may take action on a matter at a meeting only if a quorum                  exists                  with respect to that matter. The attendance of at least two (2)                  members of                  the AMC of each party at a meeting will constitute a quorum for                  the                  transaction of business. Each member of the AMC will be entitled                  to cast                  one (1) vote on any matter to be acted upon at any meeting of the                  AMC. All                  decisions made by the AMC will require *** by the members of the                  AMC                  present at the meeting. Any action required or permitted to be                  taken at                  any meeting of the AMC may be taken without a meeting if the action                  is                  taken by all members of the AMC. The action must be evidenced by                  one or                  more written consents describing the action taken and signed by                  each                  member of the AMC. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **2.7** | **Dispute                  Resolution**.                  (a)                  The parties recognize that disputes as to certain matters may from                  time to                  time arise during the Term of this Agreement that relate to either                  party's                  rights or obligations hereunder. It is the objective of the parties                  to                  establish procedures to facilitate the resolution of disputes arising                  under this Agreement or any other Collaboration Document in an                  expedient                  manner by mutual cooperation and without resort to litigation.                  To                  accomplish this objective, the parties agree to follow the procedures                  set                  forth in this Section 2.7 if and when a dispute arises under any                  Collaboration Document. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Unless                  otherwise specifically recited in a particular Collaboration Document,                  disputes between the parties under such Collaboration Document                  will be                  first referred to the AMC by either party as soon as reasonably                  possible                  after such dispute has arisen. If the AMC is unable to resolve                  such a                  dispute within fifteen (15) days of being requested by a party                  to resolve                  such dispute, either party may, by written notice to the other,                  have such                  dispute referred to their respective executive officers designated                  below                  or their designees, for attempted resolution by negotiations within                  fifteen (15) days after such notice is received. The designated                  officers                  are as follows: |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (c) | In                  the event such designated officers are unable to resolve such dispute                  within such 15-day period, then |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | to                  the extent the dispute relates to a clinical or development activity                  or                  issue, then such matter will be finally decided by                  King, |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | to                  the extent the dispute relates to a regulatory activity or issue,                  then                  such matter will be finally decided by                  King, |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | to                  the extent the dispute relates to a marketing activity or issue,                  then such                  matter will be finally decided by King,                  or |
|--------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iv) | *** |
|--------|------|-----|

|   | (d) | Disputes                  not subject to the final decision-making authority of either party,                  as                  described in Section 2.7(c)(iv) above, will be resolved by binding                  arbitration in accordance with the rules of the American Arbitration                  Association (the “**AAA**”)                  and the provisions of this Section                  2.7(d). |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | The                  party desiring to initiate an arbitration proceeding will send                  a written                  notice to the other party requesting the commencement of the arbitration                  proceeding and specifying the issue to be resolved. Within fifteen                  (15)                  days from the date such notice is sent, each party will designate                  one                  neutral arbitrator. Within fifteen (15) days thereafter, the first                  two                  arbitrators will designate a third. Each arbitrator will by training,                  education, or experience have knowledge of the subject matter of                  the                  dispute. If either party fails to choose an arbitrator within the                  foregoing time period, the AAA will choose an arbitrator on behalf                  of that                  party. Disputes about arbitration procedure will be resolved by                  the                  arbitrators or, failing agreement, by the AAA in New York, New                  York.                  Unless otherwise agreed by the parties, the arbitration proceedings                  will                  be conducted in New York, New York. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (ii) | Within                  5 days of the selection of the final arbitrator, the parties will                  deliver                  to the arbitrators a joint letter (A) stating each of the issues                  that is                  the subject of the dispute, (B) setting forth each party's final                  position                  with respect to each such issue, and (C) directing the arbitrators                  to                  resolve the dispute by selecting the final position of one of the                  parties;                  provided that, if the parties cannot agree on a joint letter, each                  party                  will submit a letter setting forth its position on each issue,                  and the                  failure of any party to submit such a joint letter will not prevent                  the                  arbitration from proceeding. In addition, each party may submit                  with the                  joint letter supporting documentation for such party's final position.                  In                  resolving the dispute, the arbitrators will have no authority to                  make a                  decision on any issue other than by selecting the final position                  of one of                  the parties. |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | An                  arbitration decision will be rendered in writing within 30 days                  of the                  submission of the letter described above, which award will be final                  and                  binding on the parties and will be deemed enforceable in any court                  having                  concurrent jurisdiction of the subject matter hereof and the parties.                  In                  selecting the final position of one of the Parties, the arbitrators                  will                  have the authority to grant specific performance and allocate costs                  between the parties (excluding attorneys' fees, which each party                  must bear                  itself); provided that the arbitrators will have no authority to                  award                  punitive damages or any damages in excess of the limitations contained                  in                  this Agreement. |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **3.** | **Budget;                  Collaboration Costs; Collaboration                  Documents** |
|--------|--------------------------------------------------------------------------------------------|

|   | **3.1** | **Marketing                  Plan and Budget**.                  (a)                  On                  or prior to October 1 of each year during the Term of this Agreement,                  the                  AMC will agree upon expense contributions to the Collaboration                  Program to                  be made by each party and will approve a marketing plan and budget                  for the                  following Calendar Year (each a “**Marketing                  Plan and Budget**”);                  provided that the Marketing Plan and Budget for the period between                  the                  Effective Date and December 31, 2005 will be approved by the AMC                  within                  one month of the Effective Date. If the parties are unable to agree                  on a                  Marketing Plan and Budget prior to October 1, the Marketing Plan                  and                  Budget applicable to the current Calendar Year will apply to the                  following                  Calendar Year until such time as the parties are able to agree                  on a new                  Marketing Plan and Budget. The initial draft of the Marketing Plan                  and                  Budget will be developed by King and Inyx for final approval by                  the AMC,                  with King developing the portions of the Marketing Plan and Budget                  relating to clauses (i) through (v) and (xi) in Section 3.1(b)                  below, and                  Inyx developing the portions relating to clauses (vi) through (x)                  below. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (b) | Each                  Marketing Plan and Budget will set forth the manner in which the                  Products                  are to be promoted during the period to which the Marketing Plan                  and                  Budget relates and will include, at a minimum: (i) the Collaboration                  Costs                  to be incurred in connection with the Collaboration Program; (ii)                  Products                  positioning, strategy, and tactics with supporting advertising                  and                  promotional activity to be undertaken; (iii) any training or sampling                  programs to be conducted; (iv) medical and education programs to                  be                  conducted; (v) public relations activities; (vi) the minimum number                  of                  quarterly and annual details to be provided by each party and targets                  therefor that will be allocated in a professionally equitable manner;                  (vii) the number of sales representatives to Detail the Products;                  (viii)                  identification of physician targets; (ix) determination of data                  and                  materials required to assess sales representatives; (x) Product                  weighting;                  and (xi) such other information relating to the marketing of the                  Products                  as deemed advisable by the AMC. Neither party will make any material                  change in any previously approved Marketing Plan and Budget without                  the                  prior written approval of the AMC. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **3.2** | **Collaboration                  Costs**. |
|--------|---------|-------------------------------------------|

|   | (a) | Allocation.                  All Collaboration Costs incurred by a party on and after the Effective                  Date through the Term of this Agreement ***. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Accounting.                  Within fifteen (15) days following the end of each Calendar Quarter,                  Inyx                  and King will submit to the AMC, or any finance committee thereof,                  an                  accounting of all Collaboration Costs incurred by it with respect                  to all                  Products and the Collaboration Program in the relevant time period.                  Within                  fifteen (15) days thereafter, the AMC will produce a report setting                  forth                  the calculation of Collaboration Costs and their allocation between                  the                  parties in accordance with Section 3.2(a) above. The report will                  also set                  forth the amount of any payments that a party must make to the                  other party                  in order to achieve *** of the Collaboration Costs as provided                  in Section                  3.2(a) above. All such payments will be made within sixty (60)                  days                  following the end of the applicable Calendar Quarter. Within thirty                  (30)                  days after the end of the Calendar Year relevant to such Calendar                  Quarters, the AMC will produce a report setting forth the calculation                  of                  aggregate Collaboration Costs incurred over the relevant Calendar                  Year and                  the allocation between the parties in accordance with Section 3.2(a)                  above. The report will also set forth the amount of any payments                  that a                  party must make to the other party in order to achieve *** of the                  Collaboration Costs as provided in Section 3.2(a) above. All such                  payments                  will be made within sixty (60) days following the end of the applicable                  Calendar Year. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (c) | Advance                  Payments and Offset.                  Each of the parties will fund projected Collaboration Costs on                  a monthly,                  prospective basis, such that all anticipated Collaboration Costs                  identified in the Marketing Plan and Budget for a given month,                  or that are                  otherwise determined by the AMC to be reasonably likely to be incurred                  in                  such month, will be allocated between the parties *** in accordance                  with                  Section 3.2(a). At the end of each Calendar Quarter, the parties                  will                  reconcile their respective funding payments pursuant to Section                  3.2(b)                  hereof, and, at the discretion of the party who has funded an amount                  greater than the Collaboration Costs allocable to such party for                  the                  relevant Calendar Quarter, such party will be reimbursed by the                  other                  party within ten (10) days after the end of such Calendar Quarter                  or, at                  its discretion, will receive a credit against Collaboration Costs                  payable                  by that party in the subsequent Calendar Quarter(s), which credit                  amount                  will be carried forward until fully                  credited. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | Currency                  Conversion.                  All Collaboration Costs incurred in currencies other than U.S.                  Dollars                  will be converted to U.S. Dollars based on the exchange rate quoted                  in The                  Wall Street Journal, NY Edition on the last business day of the                  applicable                  Calendar Quarter. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **3.3** | **Collaboration                  Costs Overruns and Additional Expenditures**.                  (a)                  Each party will use commercially reasonable efforts to complete                  all tasks                  assigned to it pursuant to the Collaboration Program in accordance                  with                  the funding allocated to such tasks in the Marketing Plan and Budget.                  In                  the event either party anticipates or becomes aware that the actual                  costs                  of any given task assigned to it may or will likely exceed the                  funds                  allocated to such task, such party will promptly notify the AMC.                  The AMC                  and any committee charged with primary oversight responsibility                  for the                  task in question will work together in good faith for up to thirty                  (30)                  days to determine whether to readjust the Marketing Plan and Budget                  to                  allocate additional funds to such task, to revise the scope of                  such task                  to permit satisfactory completion at the then-budgeted funding                  level, or                  both. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Notwithstanding                  the foregoing, either party may, in its discretion, spend additional                  amounts above and beyond those allocated in the Marketing Plan                  and Budget                  (“**Discretionary                  Funding**”)                  on any task assigned to such party pursuant to the Collaboration                  Program                  or on any other task the AMC has approved. In such event, the party                  wishing to expend Discretionary Funding will first inform the other                  party                  of its intent to do so. If such other party consents to such Discretionary                  Funding being deemed a Collaboration Cost, such Discretionary Funding                  will                  constitute a Collaboration Cost, and the rights and obligations                  of the                  parties with respect to such Collaboration Costs will be determined                  in                  accordance with the terms and conditions of the Collaboration Documents                  as                  they apply to the Collaboration Program. If such other party does                  not                  consent, then such Discretionary Funding will not constitute a                  Collaboration Cost but will be borne solely by the party undertaking                  the                  Discretionary Funding, and the parties will negotiate in good faith,                  prior                  to the expenditure of the Discretionary Funding, the rights and                  obligations of the parties with respect to such Discretionary                  Funding. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (c) | Notwithstanding                  Section 2.7(c), except to the extent this Agreement or any other                  Collaboration Document expressly provides for payments that do                  not require                  AMC approval, and except to the extent the AMC has approved any                  payment                  hereunder, neither party will (i) be obligated to incur any costs                  or                  expend any funds that have not been approved by such party or (ii)                  have                  the authority to cause the other party to incur any costs or expend                  any                  funds that have not been approved by such other                  party. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **3.4** | **Collaboration                  Documents**.                  In furtherance of the Collaboration Program, concurrently herewith,                  the                  parties are executing the following                  agreements: |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | a                  Technology Transfer Agreement, in the form attached hereto as Exhibit                  A                  (the “**Technology                  Transfer Agreement**”); |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | a                  Manufacturing and Supply Agreement, in the form attached hereto                  as Exhibit                  B (the “**Manufacturing                  and Supply Agreement**”); |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | a                  Marketing and Promotion Agreement, in the form attached hereto                  as Exhibit                  C (the “**Marketing                  and Promotion Agreement**”); |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | a                  Development Agreement, in the form attached hereto as Exhibit D                  (the                  “**Development                  Agreement**”);                  and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | a                  Quality Agreement, in the form attached hereto as Exhibit E (the                  “**Quality                  Agreement**”). |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **4.** | **Licenses** |
|--------|--------------|

|   | **4.1** | **License                  Grant**.                  Subject to the terms and conditions of this Agreement, beginning                  on the                  Effective Date and thereafter during the Term, King hereby grants                  to Inyx                  a non-exclusive limited license (without a right to sublicense                  except as                  provided in Section 4.2) under the Technology and Patent Rights                  to make,                  use, sell, offer for sale, and import Products in the Territory,                  which                  license will be exercisable by Inyx only as part of the Collaboration                  Program and only for the conduct of the activities required in                  the                  performance of its obligations or exercise of its rights under                  the                  Collaboration Documents. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **4.2** | **Sublicenses**.                  Inyx may not sublicense any of the rights granted to it pursuant                  to this                  Agreement or the other Collaboration Documents, or utilize subcontractors                  in the performance thereof, except to wholly owned subsidiaries                  of Inyx.                  In the event of a grant of a sublicense to any such subsidiary                  (or any                  other Person with King's consent), Inyx acknowledges and agrees                  that it                  will remain liable for all obligations, including obligations to                  perform,                  under the Collaboration Documents and for all actions of such subsidiaries                  (or other sublicensee) under any such sublicense. All such sublicensees                  must agree, in writing, to be bound by the terms of the Collaboration                  Documents, including the confidentiality and assignment provisions                  thereof. Inyx will notify King, in writing, of any such subsidiary                  sublicense promptly upon granting of such                  sublicense. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **4.3** | **Consultants**.                  Inyx, with the prior written consent of the AMC, may use individual                  Consultants in connection with the performance of its duties and                  the                  exercise of its rights under this Agreement and the other Collaboration                  Documents. Inyx acknowledges and agrees that it will remain liable                  for all                  obligations, including obligations to perform, under the Collaboration                  Documents and for all actions of such Consultants pursuant thereto,                  and                  Inyx will indemnify and hold King harmless from and against any                  and all                  other claims or liabilities for costs and expenses incurred by                  reason of                  any action of any Consultants. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **4.4** | **Termination                  of Collaboration Documents**.                  Inyx understands and agrees that the scope of the license granted                  in                  Section 4.1 will be reduced from time to time as each of the Collaboration                  Documents expires or terminates. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **5.** | **Intellectual                  Property Rights** |
|--------|---------------------------------------------------|

|   | **5.1** | **Inventions                  Disclosure and Generally**.                  Each party will promptly provide the AMC with written notice concerning                  all Improvements that are conceived, made, or developed by employees                  or                  Consultants of such party or its Affiliates, whether alone or jointly                  with                  the other party or its Affiliates or with permitted Third Parties.                  Such                  notice will be treated as the Confidential Information of King                  hereunder. |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **5.2** | **Ownership**.                  King will have sole and exclusive ownership of all right, title,                  and                  interest on a worldwide basis, with full rights to license or sublicense,                  subject to the licenses granted Inyx in the Collaboration Documents,                  in                  and to any and all |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | the                  Products and New Products; |
|--------|-----|-------------------------------------------------|

|   | (b) | Technology                  transferred to Inyx's facilities pursuant to the Technology Transfer                  Agreement; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Technology                  and Patent Rights as they exist as of the Effective Date;                  and |
|--------|-----|------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (d) | any                  Improvements to the Technology and all associated Patent Rights,                  developed                  during the Term, whether developed by King or Inyx or jointly by                  King and                  Inyx and any permitted Third Parties, including all rights to any                  Technology and Patent Rights related to Excluded New                  Products; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **5.3** | **Assignment**.                  Inyx agrees to, and hereby does, and will cause each of its employees,                  Consultants, Affiliates, and permitted sublicensees (collectively                  with                  Inyx, the “**Assignors**”)                  to, transfer, assign, and convey exclusively to King, its successors                  and                  assigns, forever, the entire right, title, and interest in and                  to all                  Improvements developed by each such Assignor, alone or jointly                  with each                  other or King, including all intellectual property rights associated                  therewith. Inyx further agrees, and will cause the other Assignors,                  (i) to                  promptly provide King with written notice, in sufficient detail,                  of any                  Improvements such Assignor makes pursuant to the Collaboration                  Documents                  and (ii) to provide King with such additional information and to                  execute                  and deliver, and to cause the other Assignors to execute and deliver,                  any                  documents or take any other actions or otherwise cooperate with                  King as                  may reasonably be necessary, or as King may reasonably request,                  to                  document, enforce, protect, or otherwise perfect King's rights                  in any                  Improvements, including filing any applicable patent applications. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **5.4** | **Employees**.                  Inyx agrees to have each employee enter into a written agreement                  with Inyx                  that includes an assignment to Inyx, or directly to King with respect                  to                  all Improvements, of all right, title, and interest in and to all                  work                  product and all inventions arising during the course of his or                  her                  employment with Inyx in connection with such Improvements or the                  Collaboration Program, and all intellectual property rights attaching                  thereto. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **6.** | **FILING,                  PROSECUTION, AND MAINTENANCE OF PATENT RIGHTS** |
|--------|----------------------------------------------------------------------------|

|   | **6.1** | **Patent                  Filing, Prosecution, and Maintenance**.                  During the Term of this Agreement, with respect to any Patent Rights                  arising hereunder: |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | King,                  acting through patent attorneys or agents of its choice, will be                  responsible for the preparation, filing, prosecution, and maintenance                  of                  all patents and patent applications, whether related to Technology                  or                  Patent Rights. At King's request, Inyx will reasonably cooperate                  with and                  assist King in connection with such                  activities. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Except                  as expressly provided herein, King makes no warranty with respect                  to the                  validity, perfection, or dominance of any patent or other proprietary                  right or with respect to the absence of rights in Third Parties                  that may                  be infringed by the manufacture or sale of any Product. Each party                  agrees                  to bring to the attention of the AMC any patent or patent application                  it                  discovers that relates to the Collaboration                  Program. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (c) | Except                  as provided in the Development Agreement with respect to Excluded                  Patent                  Costs, all reasonable fees and expenses of counsel and other reasonable                  costs and expenses of each party attributable to the filing, prosecution,                  and maintenance of Patent Rights or Technology used or reasonably                  expected, in the judgment of the AMC, to be used or useful in the                  Collaboration Program will be deemed Regulatory and IP                  Costs. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **6.2** | **Information                  and Cooperation**.                  King will keep the AMC regularly informed of the status of the                  Patent                  Rights and will provide to Inyx's legal counsel, subject to appropriate                  confidentiality or common interest agreements, with (a) copies                  of all                  filings and correspondence with the patent offices, administrative                  boards,                  or courts that King sends or receives in connection with filing,                  prosecution, maintenance, and defense of the Patent Rights, and                  (b) copies                  of filings and correspondence under clause (a) sufficiently in                  advance of                  the due date so as to give Inyx's legal counsel sufficient time                  to                  comment; provided nothing herein will limit King's sole right to                  file,                  prosecute, maintain, and defend the Patent Rights in its sole                  discretion. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **6.3** | **Legal                  Action**. |
|--------|---------|------------------------------------|

|   | (a) | Actual                  or Threatened Infringement. |
|--------|-----|-----------------------------------------------------|

|   | (i) | In                  the event either party becomes aware of any possible infringement                  or                  unauthorized possession, knowledge, or use of any Patent Right,                  Technology, or any Trademarks (collectively, an “**Infringement**”),                  that party will promptly notify the AMC and the other party and                  provide                  them with full details (an “**Infringement                  Notice**”).                  The AMC will make a recommendation as to which actions should be                  taken                  with respect to such matters; provided that King will have the                  final                  decision as to whether to follow such recommendation. King will                  be under                  no obligation to prosecute or prevent the Infringement of or relating                  to                  Patent Rights, Technology, or Trademarks. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | If                  the matter relates to an Excluded New Product and if King does                  not                  commence an action to prosecute, or otherwise take steps to prevent                  or                  terminate, the Infringement within one hundred eighty (180) days                  from any                  Infringement Notice, expressly excluding any immaterial infringement,                  then                  Inyx will have the right and option to take such action as Inyx                  will                  consider appropriate to prosecute or prevent such Infringement,                  but only                  if such Infringement is in the Territory. No suit instituted by                  Inyx                  pursuant to this clause (ii) may be settled without the approval                  of the                  AMC. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (iii) | All                  reasonable costs and expenses expended by a party in connection                  herewith                  will be deemed Collaboration Costs to the extent the same are related                  to a                  Product. All monies or other assets recovered by a party pursuant                  hereto                  will be allocated first to offset all costs and expenses of such                  suit, and                  all remaining amounts will be retained by                  King. |
|--------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iv) | If                  either party determines that it is necessary or desirable for the                  other to                  join any such suit, action, or proceeding, the other party will,                  upon                  written notice from the prosecuting party, execute all papers and                  perform                  such other acts as may be reasonably required in the                  circumstances. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (v) | Each                  party will always have the right to be represented by counsel of                  its own                  selection in any suit instituted under this Section 6.3 by the                  other party                  for Infringement. If either party lacks standing and the other                  party has                  standing to bring any such suit, action, or proceeding, then such                  other                  party will bring such suit at the request of the first party. |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (vi) | In                  any action under this Section 6.3, the parties will fully cooperate                  with                  and assist each other. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Defense                  of Claims. |
|--------|-----|-------------------------------------|

|   | (i) | In                  the event that any action, suit, or proceeding is brought against                  King or                  Inyx or any Affiliate of either party alleging the infringement                  of the                  technology or intellectual property rights of a Third Party by                  reason of                  any party's activities performed pursuant to the Collaboration                  Documents,                  the AMC will determine how the parties will defend themselves in                  such                  action. All costs related to the same will be deemed Regulatory                  and IP                  Costs. Each party will have the right to separate counsel in any                  such                  action or proceeding. The parties will cooperate with each other                  in the                  defense of any such suit, action, or proceeding; provided, however,                  that                  King will have the option to assume control of the defense of any                  action,                  suit, or proceeding. The parties will give each other prompt written                  notice of the commencement of any such suit, action, or proceeding                  or                  claim of infringement and will furnish each other a copy of each                  communication relating to the alleged infringement. King, in its                  sole                  discretion, may compromise, litigate, settle, or otherwise dispose                  of any                  such suit, action, or proceeding. If the defending party agrees                  that the                  other party should institute or join any suit, action, or proceeding                  pursuant to this Section 6.3, the defending party may join the                  other party                  as a party to the suit, action, or proceeding, and the party so                  joined                  will execute all documents and take all other actions, including                  giving                  testimony, that may reasonably be required in connection with the                  prosecution of such suit, action, or                  proceeding. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (ii) | If                  as a consequence of such action, suit, or proceeding by a Third                  Party                  claiming that the discovery, development, manufacture, use, or                  sale of a                  Product or Excluded New Product infringes such Third Party's intellectual                  property rights, the parties will examine and discuss in good faith                  the                  consequences of such prohibition or restriction or other conditions                  on                  this Agreement and the other Collaboration Documents and on possible                  modifications thereto. |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **6.4** | **Trademark                  Prosecution**.                  King will be responsible for the filing, prosecution, defense,                  and                  maintenance before all trademark offices of any Trademarks applicable                  to                  the Products and the Excluded New Products, and all related and                  reasonable                  costs and expenses will be deemed Regulatory and IP                  Costs. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **7.** | **Obligations                  OF INYX** |
|--------|------------------------------------------|

|   | **7.1** | *                  *                  * |
|--------|---------|-----------------------------------------|

|   | **7.2** | ***                  * *** |
|--------|---------|----------------------------|

| **8.** | **Obligations                  OF KING** |
|--------|------------------------------------------|

|   | **8.1** | ***                  * *** |
|--------|---------|----------------------------|

|   | **8.2** | ***                  * *** |
|--------|---------|----------------------------|

|   | **8.3** | **Manufacturing                  Right of First Negotiation**.                  Subject to the terms and conditions of this Section 8.3, during                  the Term,                  King grants to Inyx a right of first negotiation with respect to                  the                  manufacture of any products of King in the respiratory field not                  already                  manufactured pursuant to the Manufacturing and Supply Agreement                  (a                  “**King                  Respiratory Product**”).                  In the event that King elects to have a party other than King or                  its                  Affiliates manufacture a King Respiratory Product, King will deliver                  to                  Inyx a written notice (the “**Manufacturing                  Offer Notice**”)                  identifying the King Respiratory Product and the price and terms,                  if any,                  upon which King proposes to have such King Respiratory Product                  manufactured. Inyx will have fifteen (15) business days following                  the                  receipt of any such Manufacturing Offer Notice to notify King in                  writing                  of Inyx's election to negotiate with King. Upon receipt of Inyx's                  election, King will negotiate exclusively with Inyx for a period                  of                  forty-five (45) days with respect to the manufacture of such King                  Respiratory Product, based on the price and terms, if any, set                  out in the                  Manufacturing Offer Notice. In the event the parties fail to come                  to terms                  regarding the manufacture of the King Respiratory Product within                  the                  aforesaid period, or, if having agreed to terms, the parties are                  unable to                  enter definitive agreements within thirty (30) days following such                  agreement, then King will be free to enter into an agreement with                  a Third                  Party to manufacture such King Respiratory Product on terms and                  conditions                  agreed to by King and such Third                  Party. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **8.4** | *** |
|--------|---------|-----|

| **9.** | **CERTAIN                  REGULATORY MATTERS** |
|--------|-------------------------------------------------|

|   | **9.1** | **Regulatory                  Filings**.                  King will be responsible for filing, obtaining, and maintaining                  Regulatory                  Approvals in connection with the Collaboration Program, including                  all                  Excluded New Products and including making all Regulatory Filings;                  and all                  such approvals, including any NDAs and INDs, will be owned by and                  held in                  the name of King. |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **9.2** | **AMC                  Oversight**.                  King will provide the AMC with reports on the progress of all Regulatory                  Filings and communications with Regulatory Authorities in the Territory                  and, if requested by the AMC, with (i) copies of all Regulatory                  Filings                  relating to the Territory and (ii) copies of all correspondence                  with                  Regulatory Authorities in the Territory. To the extent practicable                  and                  consistent with applicable laws, King will afford Inyx a reasonable                  opportunity to comment on such Regulatory Filings; provided that                  nothing                  herein will limit King's sole right to oversee such Regulatory                  Filings. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **9.3** | **Inyx's                  Responsibilities**.                  Inyx agrees to cooperate with King with respect to the activities                  hereunder, including as follows: |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | to                  make Inyx's personnel reasonably available, upon reasonable notice                  of                  King, at such personnel's place of employment to consult with King                  on                  issues arising related to the activities conducted in accordance                  with this                  Article 9 or otherwise relating to regulatory matters involving                  the                  Products or Excluded New Products, including any request from any                  Regulatory Authority, including regulatory, scientific, technical,                  and                  clinical testing issues, or                  otherwise; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | to                  cooperate with King, at King's request, to comply with specific                  requests                  of a Regulatory Authority with respect to data supplied or to be                  supplied                  for filing with such Regulatory Authority, or with respect to Products                  supplied by King; and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | from                  time to time, or upon reasonable request, during the term of this                  Agreement, to transfer to King all previously undisclosed data                  relating to                  the Products and Excluded New Products that is in Inyx's possession                  or                  control. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **9.4** | **Regulatory                  Costs**.                  All costs and expenses associated with filing, obtaining, and maintaining                  Regulatory Approvals in connection with the Collaboration Program                  will be                  deemed Regulatory and IP Costs. |
|--------|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **9.5** | **Licenses**.                  Each party hereto will, at its sole cost and expense, maintain                  in full                  force and effect all necessary licenses, permits, and other authorizations                  required by law, regulation, ordinance, or statute to carry out                  its duties                  and obligations under the Collaboration                  Documents. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **10.** | **RECORDKEEPING                  AND AUDITS** |
|---------|-----------------------------------------------|

|   | **10.1** | **Maintenance                  of Books and Records**.                  Each party will maintain complete and accurate books and records                  in                  sufficient detail, in accordance with GAAP and all applicable laws,                  rules,                  ordinances, and regulations, to enable verification of the performance                  of                  such party's obligations under the Collaboration Documents and                  verification of the Collaboration Costs incurred by such party.                  Such                  records will be maintained for a period of twenty-four (24) months                  after                  the end of the Term or longer if required by applicable law. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **10.2** | **Payment                  Audits**.                  (a)                  Either party (herein, the “**Auditing                  Party**”)                  may demand, no more than once during any Calendar Year from the                  Effective                  Date until two (2) years following the end of the Term, an audit                  of the                  relevant books and records of the other party (herein, the “**Audited                  Party**”)                  in order to verify the Audited Party's reports with respect to                  Collaboration Costs and any payments required under the Collaboration                  Documents. Upon no less than fifteen (15) days' prior written notice                  to                  the Audited Party, the Audited Party will grant access to the relevant                  books and records of the Audited Party to members of a nationally                  recognized independent public accounting firm selected by the Auditing                  Party in order to conduct a review or audit thereof. Such access                  will be                  available during normal business hours. The accountants will report                  their                  conclusions and calculations to the Auditing Party and the Audited                  Party;                  provided that in no event will the accountants disclose any information                  of                  the Audited Party except to the extent necessary to verify the                  Audited                  Party's reporting and other compliance with the terms of this Agreement,                  and, at the request of the Audited Party, such accountants will                  execute                  appropriate non-disclosure agreements. Except as hereinafter set                  forth,                  the Auditing Party will bear the full cost of the performance of                  any such                  audit. |
|--------|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | If,                  as a result of any audit of the books and records of Audited Party,                  it is                  shown that the payments from one party to the other under this                  Agreement                  with respect to the period of time audited were less than or more                  than the                  amount that should have been paid, or it is shown that the Collaboration                  Costs claimed by the Audited Party were overstated, then the parties                  will                  reconcile the amounts owed by each party to the other. In addition,                  if                  such audit demonstrates that Collaboration Costs were overstated                  or                  revenue underreported by more than *** for the period audited,                  then the                  Audited Party will also reimburse the Auditing Party for its documented                  reasonable out-of-pocket costs and expenses incurred in connection                  with                  the audit. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **10.3** | **Compliance                  Audits**. (a)                  In                  addition to the access and audit rights of the parties set forth                  in                  Section 10.2, no more than once during any Calendar Year during                  the Term,                  upon reasonable prior notice, each party (the “**Requested                  Party**”)                  will, and will cause its Affiliates to, afford to the other party                  (the                  “**Requesting                  Party**”)                  reasonable access during normal business hours (and at such other                  times as                  the parties may mutually agree) to such of the Requested Party's                  relevant                  books, records, and other information as the Requesting Party may                  reasonably request in order to monitor the Requested Party's compliance                  with such party's obligations under the Collaboration Program.                  Such access                  will be available during normal business hours. Any inspection                  conducted                  by either party pursuant to this Section 10.3 will be at the sole                  cost and                  expense of the Requesting Party. |
|--------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **11.** | **TERM                  AND TERMINATION** |
|---------|-------------------------------------------|

|   | **11.1** | **Term                  of Agreement**.                  The term of this Agreement (the “**Term**”)                  will commence as of the Effective Date hereof and will continue,                  unless                  terminated sooner or extended as provided below, until the earlier                  of (i)                  the later of December 31, 2015 and the last date on which any Approved                  New                  Product is sold and (ii) expiration or termination of the last                  of the                  other Collaboration Documents. |
|--------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.2** | **Termination                  by Either Party**. (a)                  Each party will have the right to terminate this Agreement at any                  time                  upon written notice to the other party, if such other party breaches                  in a                  material way any of the representations, warranties, covenants,                  or                  agreements set forth in this Agreement or otherwise materially                  defaults in                  the performance of any of its duties or obligations under this                  Agreement,                  which breach or default is not cured within sixty (60) days after                  written                  notice is given to the breaching party specifying the breach or                  default. |
|--------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Each                  party may, by written notice delivered to the breaching party,                  terminate                  this Agreement if there are two or more similar or substantially                  similar                  material breaches of this Agreement by the breaching party within                  any                  12-month period, which termination will be effective thirty (30)                  days                  following such written notice; provided, however, that any failure                  of a                  non-breaching party to exercise this termination right with respect                  to                  certain breaches will not be deemed a waiver of the ability of                  such                  non-breaching party to exercise this right upon any subsequent                  breach. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | To                  the extent permitted by law, each party will have the right to                  terminate                  this Agreement immediately upon notice to the other party, if such                  other                  party is declared bankrupt or insolvent, if there is an assignment                  for the                  benefit of creditors, or if a receiver is appointed or proceedings                  commenced (and not dismissed within sixty (60) days), voluntarily                  or                  involuntarily, under any bankruptcy or similar                  law. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **11.3** | **Termination                  by King**. (a)                  King will have the right to terminate this Agreement immediately                  upon                  written notice to Inyx if (i) subject to the terms of Section 11.3(b)                  below, there is a Change of Control of Inyx, or (ii) the Manufacturing                  and                  Supply Agreement terminates. |
|--------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | *                  *                  * |
|--------|-----|-----------------------------------------|

|   | **11.4** | **Effects                  of Termination**. (a)                  Upon termination or expiration of this Agreement, all other Collaboration                  Documents, except the Manufacturing and Supply Agreement and the                  Quality                  Agreement, and the Development Agreement (to the extent provided                  in                  Section 7.3 of such agreement), will concurrently                  terminate. |
|--------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Neither                  the termination nor expiration of this Agreement will release or                  operate                  to discharge either party from any liability or obligation that                  may have                  accrued prior to such termination or expiration. Any termination                  of this                  Agreement as provided herein will not be an exclusive remedy but                  will be                  in addition to any remedies whatsoever that may be available to                  the                  terminating party. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Notwithstanding                  the giving of any notice of termination pursuant to this Article                  11, each                  party will continue to fulfill its obligations under this Agreement                  at all                  times until the effective date of any such                  termination. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.5** | **Actions                  Upon Termination**.                  Upon the termination or expiration of this Agreement for any reason, |
|--------|----------|--------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Except                  as provided in a concurrently terminating Collaboration Document,                  Inyx                  will immediately cease all uses of the license granted hereunder; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Inyx                  will deliver to King all Improvements and all documents, material,                  data,                  records, analyses, and information related thereto;                  and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | The                  parties will cooperate with each other, including by making their                  personnel and other resources reasonably available to each other                  as                  necessary, for a period of ninety (90) days to effect an orderly                  termination of the Collaboration Program and an orderly transition                  of                  Collaboration Program responsibilities to                  King. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.6** | **Survival**.                  The provisions of Articles 2 (to the extent necessary for the AMC                  to                  perform the actions assigned to it following termination or expiration                  of                  this Agreement or any other Collaboration Document), 5, 11, 12,                  13, and 15                  and Sections 10.1, 10.2, and 14.3 will survive any expiration or                  termination of this Agreement. |
|--------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.7** | **Payments                  Upon Termination**. (a)                  The                  expiration or termination of this Agreement pursuant to this Article                  11                  will not release either party from any obligation to pay to the                  other                  party any amounts accrued under any of the Collaboration Documents                  in                  connection with activities completed, Collaboration Costs incurred,                  and                  revenue realized with respect to the period prior to the effective                  date of                  such expiration or termination. |
|--------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (b) | Within                  thirty (30) days after the expiration or termination of this Agreement,                  each party will provide to the other (i) a reasonably detailed                  statement of Collaboration Costs incurred by such party during                  the period                  of January 1 of the Calendar Year in which such expiration                  or                  termination occurs through the effective date of such expiration                  or                  termination; and (ii) any final reports with respect to                  revenue or                  Net Sales relating to the Products during such period, as required                  by any                  of the other Collaboration                  Documents. |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Within                  thirty (30) days after receipt of such information, the AMC will                  determine                  the net amounts due and or payable by Inyx and King, and such amounts                  will                  be paid by the parties within thirty (30) days after such AMC                  determination. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **11.8** | **Effects                  of Termination of any Collaboration Document**.                  Upon termination or expiration of any Collaboration Document (the                  “**Terminated                  Agreement**”),                  except to the extent of the survival of any provisions thereof,                  all                  references to Collaboration Documents herein will not include a                  reference                  to such Terminated Agreement. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **12.** | **CONFIDENTIALITY;                  Announcements** |
|---------|-----------------------------------------------------|

|   | **12.1** | **Confidential                  Information**. (a)                  Each party acknowledges that it may receive confidential or proprietary                  information (the “**Confidential                  Information**”)                  of the other party in the performance of the Collaboration Documents,                  including information obtained or reviewed in connection with any                  audits                  or investigations performed pursuant to Section 10.2 or Section                  10.3 of                  this Agreement. Each party will hold confidential and will not,                  directly                  or indirectly, disclose, publish, or use for the benefit of any                  Third                  Party or itself, except in carrying out its duties under the Collaboration                  Documents, any confidential or proprietary information of the other                  party                  or confidential or proprietary information jointly developed by                  the                  parties, without first having obtained the furnishing party's written                  consent to such disclosure or use. “**Confidential                  Information**”                  will include know-how, scientific information, clinical data, efficacy                  and                  safety data, adverse event information, formulas, methods and processes,                  specifications, pricing information (including discounts, rebates,                  and                  other price adjustments), and other terms and conditions of sales,                  customer information, business plans, and all other intellectual                  property.                  The Patent Rights and Technology will be deemed the Confidential                  Information of King. The restrictions in this Article 12 will not                  apply to                  any information that: |
|--------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (i) | is                  or becomes part of the public domain other than by unauthorized                  acts of                  the receiving party or its Affiliates, sublicensees, Consultants,                  and                  contractors, as applicable; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | can                  be shown by written documentation to have been disclosed to the                  receiving                  party or its Affiliates or sublicensees by a Third Party who was                  not                  otherwise prohibited from transmitting the information to the receiving                  party by a contractual, legal, or fiduciary obligation of confidence                  to                  the disclosing party; |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | prior                  to disclosure under this Agreement, was already in the possession                  of the                  receiving party or its Affiliates or sublicensees, provided such                  information was not obtained directly or indirectly from the other                  party                  hereto pursuant to a confidentiality                  agreement; |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iv) | can                  be shown by written documentation to have been independently developed                  by                  the receiving party or its Affiliates without breach of any of                  the                  provisions of this Agreement, including without reference to the                  Confidential Information of the disclosing                  party; |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (v) | is                  disclosed by the receiving party pursuant to oral questions,                  interrogatories, requests for information or documents, subpoena,                  or a                  civil investigative demand of a court or governmental agency; provided,                  however, that the receiving party notifies the other party promptly                  following receipt thereof so that the other may seek a protective                  order or                  other appropriate remedy to prevent or limit such disclosure; and                  provided                  further that the receiving party furnishes only that portion of                  the                  information that it is advised by counsel is legally required and                  imposes                  such obligations of secrecy as are possible in that                  regard; |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (vi) | is                  required or permitted to be disclosed by the receiving party under                  any                  statutory, regulatory, or similar legislative requirement or any                  rule of                  any stock exchange to which it or any Affiliate is subject; provided,                  however, that the other party will be allowed to review the proposed                  disclosure and the receiving party agrees to consider in good faith                  any                  proposed revisions thereof provided to the receiving party within                  two (2)                  business days of the other party's receipt of the proposed disclosure,                  and                  the parties will seek confidential treatment for such disclosure                  as                  permitted by applicable law; or |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (vii) | is                  required by authorities to obtain Regulatory                  Approval. |
|--------|-------|---------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (b) | The                  receiving party agrees that it will disclose the Confidential Information                  only to its employees and Consultants who need to know such Confidential                  Information for such party to perform its obligations hereunder.                  The                  receiving party agrees (i) to inform all of its employees and Consultants                  who receive Confidential Information of the confidential nature                  thereof                  and to direct all such employees and Consultants to treat the Confidential                  Information confidentially in accordance with this Agreement; (ii)                  to be                  responsible for any breach of the Agreement by any of its employees                  and                  Consultants; and (iii) to make all reasonable, necessary, and appropriate                  efforts to safeguard the Confidential Information from disclosure                  other                  than as permitted hereby, which will include requiring all employees                  and                  Consultants who have access to Confidential Information of the                  disclosing                  party to execute written obligations to maintain the same in confidence                  and not to use such information except as expressly permitted under                  the                  Collaboration Documents. Each party agrees to enforce confidentiality                  obligations to which its employees and Consultants are                  obligated. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Upon                  the expiration or termination of this Agreement or upon request                  of the                  disclosing party, the receiving party will return to the disclosing                  party                  any and all Confidential Information of the disclosing party and                  any                  reproductions thereof. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | The                  obligations set forth in this Article 12 will survive the termination                  or                  expiration of this Agreement for a period of five (5) years (or,                  in the                  case of any Confidential Information identified as a trade secret                  by the                  disclosing party at the time of disclosure, for so long as such                  trade                  secret Confidential Information is susceptible of remaining a trade                  secret).** ** |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **12.2** | **Public                  Announcements**.                  The form and content of any public announcement to be made by one                  party                  regarding this Agreement, any of the other Collaboration Documents,                  or the                  Collaboration Program, or the subject matter contained in the                  Collaboration Documents, will be subject to the prior written consent                  of                  the other party (which consent will not be unreasonably withheld,                  delayed,                  or conditioned), except as may be required by applicable law (including                  disclosure requirements of the Securities and Exchange Commission,                  the New                  York Stock Exchange, NASDAQ, or any other stock exchange), in which                  event                  such party will endeavor to give the other party reasonable advance                  notice                  and review of any such disclosure. |
|--------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **13.** | **INDEMNIFICATION                  AND INSURANCE** |
|---------|----------------------------------------------------|

|   | **13.1** | **Indemnification                  by Inyx**.                  Inyx will defend, indemnify, and hold King and its Affiliates,                  and their                  respective officers, directors, employees, agents, successors,                  and                  assigns, harmless from and against any and all Third Party claims,                  liabilities, losses, costs, actions, suits, judgments, damages,                  and                  expenses (including attorneys' fees and costs) arising out of:                  (a) any breach by Inyx of any representation, warranty,                  or covenant                  contained in the Collaboration Documents; (b) the negligence                  or                  willful misconduct of Inyx, its Affiliates, or their respective                  employees                  or agents in the performance of any obligation under the Collaboration                  Documents; and (c) any claims relating to the performance or                  nonperformance of Inyx's obligations under the Collaboration Documents;                  provided, however, that Inyx will not be required to indemnify                  King with                  respect to any such claim, liability, loss, cost, action, suit,                  damage, or                  expense hereunder to the extent the same is caused primarily by                  any breach                  of contract, negligent act or omission or intentional misconduct                  by King                  or any or its Affiliates or is otherwise covered by King's indemnification                  obligation in Section 13.2. |
|--------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **13.2** | **Indemnification                  by King**.                  King will defend, indemnify, and hold Inyx and its Affiliates,                  and their                  respective officers, directors, employees, agents, successors,                  and                  assigns, harmless from and against any and all Third Party claims,                  liabilities, losses, costs, actions, suits, judgments, damages,                  and                  expenses (including attorneys' fees and costs) arising out of:                  (a) any breach by King of any representation, warranty,                  or covenant                  contained in the Collaboration Documents; (b) the negligence                  or                  willful misconduct of King, its Affiliates, or their respective                  employees                  or agents in the performance of any obligation under the Collaboration                  Documents; and (c) any claims relating to the performance or                  nonperformance of King's obligations under the Collaboration Documents;                  provided, however, that King will not be required to indemnify                  Inyx with                  respect to any such claim, liability, loss, cost, action, suit,                  damage, or                  expense hereunder to the extent the same is caused primarily by                  any breach                  of contract, negligent act or omission or intentional misconduct                  by Inyx                  or any or its Affiliates or is otherwise covered by Inyx's indemnification                  obligation in Section 13.1. |
|--------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **13.3** | **Claims                  Procedures**.                  A                  party (the “**indemnitee**”)                  that intends to claim indemnification under this Article 13 will                  notify                  the other party (the “**indemnitor**”)                  within a reasonable time in writing of any action, claim, or liability                  in                  respect of which the indemnitee believes it is entitled to claim                  indemnification; provided that the failure to give timely notice                  to the                  indemnitor will not release the indemnitor from any liability to                  the                  indemnitee except to the extent the indemnitor is actually prejudiced                  thereby. The indemnitor will have the right, by notice to the indemnitee,                  to assume the defense of any such action or claim within the fifteen                  (15)                  day period after the indemnitor's receipt of notice of any action                  or claim                  with counsel of the indemnitor's choice and at the sole cost of                  the                  indemnitor. If the indemnitor does not so assume the defense of                  such Third                  Party claim, the indemnitee may assume such defense with counsel                  of its                  choice and at the sole cost of the indemnitor. If the indemnitor                  so                  assumes such defense, the indemnitee may participate therein through                  counsel of its choice, but at the sole cost of the indemnitee.                  The party                  not assuming the defense of any such claim will render all reasonable                  assistance to the party assuming such defense, and all reasonable                  out-of-pocket costs of such assistance will be for the account                  of the                  indemnitor. No such claim will be settled other than by the party                  defending the same, and then only with the consent of the other                  party,                  which will not be unreasonably withheld; provided that the indemnitee                  will                  have no obligation to consent to any settlement of any such action                  or                  claim that imposes on the indemnitee any liability or obligation                  that                  cannot be assumed and performed in full by the indemnitor, and                  the                  indemnitee will have no right to withhold its consent to any settlement                  of                  any such action or claim if the settlement involves only the payment                  of                  money by the indemnitor or its                  insurer. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **13.4** | **Insurance**.                  During the Term, each party will maintain insurance (either through                  purchase of a policy from a nationally recognized Third Party insurer                  or                  through maintenance of a self-insurance program) against such risks                  and                  upon such terms (including coverages, deductible limits, and self-insured                  retentions) as is customary for the activities to be conducted                  by such                  party under this Agreement and is appropriate to cover its indemnification                  obligations hereunder. Each party will name the other as an additional                  insured on such party's relevant insurance policies and will furnish                  to                  the other party evidence of such insurance, upon                  request. |
|--------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **13.5** | **Limited                  Liability**.                  NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT OR ANY                  OTHER                  COLLABORATION DOCUMENT, NEITHER KING NOR INYX WILL BE LIABLE WITH                  RESPECT                  TO ANY SUBJECT MATTER OF THE COLLABORATION DOCUMENTS UNDER ANY                  CONTRACT,                  NEGLIGENCE, STRICT LIABILITY, OR OTHER LEGAL OR EQUITABLE THEORY                  FOR (I)                  ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES                  OR                  (II) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY, OR                  SERVICES. |
|--------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **14.** | **REPRESENTATIONS                  AND WARRANTIES** |
|---------|-----------------------------------------------------|

|   | **14.1** | **By                  Inyx**.                  Inyx represents and warrants to King                  that: |
|--------|----------|------------------------------------------------------------------------------------------------------------|

|   | (a) | the                  execution, delivery, and performance of each Collaboration Document                  by                  Inyx does not conflict with, or constitute a breach of or under,                  any                  order, judgment, agreement, or instrument to which Inyx is a party; |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | the                  execution, delivery, and performance of each Collaboration Document                  by                  Inyx does not require the consent of any Person or the authorization                  of                  (by notice or otherwise) any governmental or regulatory authority; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | each                  Collaboration Document is a legal, valid, and binding obligation                  of Inyx                  enforceable against it in accordance with its terms and conditions,                  except                  as enforceability may be limited by bankruptcy, insolvency, or                  other laws                  affecting the enforcement of creditors' rights generally, and except                  that                  the availability of the remedy of specific performance or other                  equitable                  relief is subject to the discretion of the court before which any                  proceeding therefor may be brought;                  and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | (d) | As                  of the Effective Date, neither Inyx nor any of its employees or                  agents, in                  their capacity as such, have been disqualified or debarred by the                  FDA,                  pursuant to 21 U.S.C. §§ 335(a) or (b), or been charged with or convicted                  under United States law for conduct relating to the development                  or                  approval, or otherwise relating to the regulation of any Product                  under the                  Generic Drug Enforcement Act of 1992, or any other relevant law,                  rule, or                  regulation or been disbarred, disqualified, or convicted under                  or for any                  equivalent or similar applicable foreign law, rule, or regulation. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **14.2** | **By                  King**.                  King represents and warrants to Inyx                  that: |
|--------|----------|------------------------------------------------------------------------------------------------------------|

|   | (a) | the                  execution, delivery, and performance of each Collaboration Document                  by                  King does not conflict with, or constitute a breach of or under,                  any                  order, judgment, agreement, or instrument to which King is a                  party; |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | the                  execution, delivery, and performance of each Collaboration Document                  by                  King does not require the consent of any Person or the authorization                  of                  (by notice or otherwise) any governmental or regulatory authority; |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | each                  Collaboration Document is a legal, valid, and binding obligation                  of King                  enforceable against it in accordance with its terms and conditions,                  except                  as enforceability may be limited by bankruptcy, insolvency, or                  other laws                  affecting the enforcement of creditors' rights generally, and except                  that                  the availability of the remedy of specific performance or other                  equitable                  relief is subject to the discretion of the court before which any                  proceeding therefor may be brought;                  and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | As                  of the Effective Date, neither King nor any of its employees or                  agents, in                  their capacity as such, have been disqualified or debarred by the                  FDA,                  pursuant to 21 U.S.C. §§ 335(a) or (b), or been charged with or convicted                  under United States law for conduct relating to the development                  or                  approval, or otherwise relating to the regulation of any Product                  under the                  Generic Drug Enforcement Act of 1992, or any other relevant law,                  rule, or                  regulation or been disbarred, disqualified, or convicted under                  or for any                  equivalent or similar applicable foreign law, rule, or                  regulation. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **14.3** | **Warranty                  Disclaimer**.                  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER                  PARTY                  MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES,                  RIGHTS, OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS                  WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,                  AND                  NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE                  FOREGOING. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

| **15.** | **MISCELLANEOUS                  PROVISIONS** |
|---------|-----------------------------------------------|

|   | **15.1** | **Notices****.**Except                  as otherwise specifically provided herein, any notice or other                  documents                  to be given under this Agreement will be in writing and will be                  deemed to                  have been duly given if sent by registered post, nationally recognized                  overnight courier, or confirmed facsimile transmission to a party                  (followed by hard copy by mail), or delivered in person to a party                  at the                  address or facsimile number set out below for such party or such                  other                  address as the party may from time to time designate by written                  notice to                  the other: |
|--------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **15.2** | **Assignment**.                  Inyx may not assign or otherwise transfer this Agreement or any                  interest                  herein or right hereunder without the prior written consent of                  King, and                  any such purported assignment, transfer, or attempt to assign or                  transfer                  any interest herein or right hereunder will be void and of no effect.                  King                  may freely assign and otherwise transfer this Agreement or any                  interest                  herein or right hereunder without Inyx's consent. Subject to the                  foregoing, this Agreement will be binding upon and inure to the                  benefit of                  the parties hereto and their respective permitted successors and                  assigns. |
|--------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.3** | **Governing                  Law**.                  This Agreement will be construed under and in accordance with,                  and                  governed in all respects by, the laws of the State of New York,                  without                  regard to its conflicts of law                  principles. |
|--------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.4** | **Non-Waiver**.                  The failure of either party to enforce or to exercise, at any time                  or for                  any period of time, any term of or any right arising pursuant to                  this                  Agreement does not constitute, and will not be construed as, a                  waiver of                  such term or right, and will in no way affect that party's right                  later to                  enforce or exercise such term or                  right. |
|--------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.5** | **Entire                  Agreement**.                  This Agreement, together with the other Collaboration Documents,                  contains                  all of the terms agreed to by the parties regarding the subject                  matter                  hereof and thereof and supersede any prior agreements, understandings,                  or                  arrangements between them, whether oral or in writing. This Agreement                  may                  not be amended, modified, altered, or supplemented except by means                  of a                  written agreement or other instrument executed by both of the parties                  hereto. No course of conduct or dealing between the parties will                  act as a                  modification or waiver of any provisions of this                  Agreement. |
|--------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.6** | **Consent                  to Jurisdiction**.                  Each of the parties hereby submits to the exclusive general jurisdiction                  of the courts of the State of New York and the courts of the United                  States                  of America for the Eastern District of New York in any action or                  proceeding arising out of or relating to this Agreement and to                  the                  jurisdiction of the appellate courts to which appeals are required                  to be                  taken from any of the foregoing. Each of the parties waives any                  defense of                  inconvenient forum to the maintenance of any such action or proceeding.                  Any party may make service on any other party by sending or delivering                  a                  copy of the process to the party to be served at the address and                  in the                  manner provided for the giving of notices in Section 15.1 above.                  Nothing                  in this Section 15.6, however, will affect the right of any party                  to serve                  legal process in any other manner permitted by law or                  equity. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **15.7** | **Equitable                  Relief**.                  Each party acknowledges that a breach by it of the provisions of                  this                  Agreement, including the provisions of Articles 5 and 12 and Section                  7.1,                  cannot reasonably or adequately be compensated in damages in an                  action at                  law and that such a breach may cause the other party irreparable                  injury                  and damage. By reason thereof, each party agrees that the other                  party is                  entitled to seek, in addition to any other remedies it may have                  under this                  Agreement or otherwise, preliminary and permanent injunctive and                  other                  equitable relief to prevent or curtail any breach of this Agreement                  by the                  other party; provided, however, that no specification in this Agreement                  of                  a specific legal or equitable remedy will be construed as a waiver                  or                  prohibition against the pursuing of other legal or equitable remedies                  in                  the event of such a breach. Each party agrees that the existence                  of any                  claim, demand, or cause of action of it against the other party,                  whether                  predicated upon this Agreement, or otherwise, will not constitute                  a                  defense to the enforcement by the other party, or its successors                  or                  assigns, of the covenants contained in this                  Agreement. |
|--------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.8** | **Severability**.                  In the event that any of the provisions or a portion of any provision                  of                  this Agreement is held to be invalid, illegal, or unenforceable                  by a court                  of competent jurisdiction or a governmental authority, such provision                  or                  portion of provision will be construed and enforced as if it had                  been                  narrowly drawn so as not to be invalid, illegal, or unenforceable,                  and the                  validity, legality, and enforceability of the enforceable portion                  of any                  such provision and the remaining provisions will not be adversely                  affected                  thereby. |
|--------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.9** | **Relationship                  of the Parties**.                  The parties hereto are acting and performing as independent contractors,                  and nothing in this Agreement creates the relationship of partnership,                  joint venture, sales agency, or principal and agent. Neither party                  is the                  agent of the other, and neither party may hold itself out as such                  to any                  other party. All financial obligations associated with each party's                  business will be the sole responsibility of such                  party. |
|--------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.10** | **Counterparts**.                  This Agreement will become binding when any one or more counterparts                  hereof, individually or taken together, will bear the signatures                  of each                  of the parties hereto. This Agreement may be executed in any number                  of                  counterparts, each of which will be deemed an original as against                  the                  party whose signature appears thereon, but all of which taken together                  will constitute but one and the same                  instrument. |
|--------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **15.11** | **Force                  Majeure**.                  Neither party will be liable to the other party for any failure                  to perform                  as required by this Agreement if the failure to perform is due                  to                  circumstances reasonably beyond such party's control including                  acts of                  God, civil disorders or commotions, acts of aggression, fire, explosions,                  floods, drought, war, sabotage, embargo, utility failures, material                  shortages, a national health emergency, or appropriations of property.                  A                  party whose performance is affected by a *force                  majeure*                  event will take prompt action using its reasonable best efforts                  to remedy                  the effects of the *force                  majeure*                  event. If, as a result of a *force                  majeure*                  event, a party is unable to fully perform its obligations hereunder                  for                  any consecutive period of one hundred eighty (180) days, the other                  party                  will have the right to terminate this Agreement, upon providing                  written                  notice to the nonperforming party, such termination to be effective                  thirty                  (30) days from the date of such notice. |
|--------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.12** | **Interpretation**.                  The parties hereto acknowledge and agree that: (a) each                  party and its                  representatives have reviewed and negotiated the terms and provisions                  of                  this Agreement and have contributed to its revision; and (b) the                  terms and provisions of this Agreement will be construed fairly                  as to each                  party hereto and not in favor of or against either party regardless                  of                  which party was generally responsible for the preparation or drafting                  of                  this Agreement. |
|--------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.13** | **Certain                  Expenses and Commissions**.                  Except as otherwise expressly set forth in this Agreement or the                  other                  Collaboration Documents, the parties hereto will each pay all their                  costs                  and expenses, including legal and accounting fees, incurred in                  connection                  with the preparation, negotiation, execution, and delivery of the                  Collaboration Documents and will indemnify and hold the other harmless                  from and against any and all other claims or liabilities for such                  costs                  and expenses incurred by reason of any action taken by any such                  party. |
|--------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.14** | **Further                  Assurances**.                  Each of Inyx and King agrees to duly execute and deliver, or cause                  to be                  duly executed and delivered, such further instruments and do and                  cause to                  be done such further acts and things, including the filing of such                  additional assignments, agreements, documents, and instruments,                  that may                  be necessary or as the other party hereto may at any time and from                  time to                  time reasonably request in connection with the Collaboration Documents                  or                  to carry out more effectively the provisions and purposes of, or                  to better                  assure and confirm unto such other party its rights and remedies                  under,                  the Collaboration Documents. |
|--------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.15** | **Conflict**.                  In the event of a conflict between the terms, conditions, and provisions                  of this Agreement and any other Collaboration Document, the terms,                  conditions, and provisions of this Agreement shall                  govern. |
|--------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **15.16** | **Third                  Party Beneficiaries**.                  This Agreement is not intended to confer upon any non-party rights                  or                  remedies hereunder, except as may be received or created as part                  of a                  valid assignment. |
|--------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**CONFIDENTIAL            TREATMENT**

----

|   | **15.17** | **Use                  of Party's Name**.                  Except as expressly provided or contemplated hereunder and except                  as                  otherwise required by applicable law, no right is granted pursuant                  to this                  Agreement to either party to use in any manner the trademarks or                  name of                  the other party, or any other trade name, service mark, or trademark                  owned                  by or licensed to the other party in connection with the performance                  of                  the Agreement. Notwithstanding the above, either party will be                  permitted                  to use the other party's name and marks, as may be required under                  applicable law, in connection with securities or other public                  filings. |
|--------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|         |                                      |                                   |
|--------------|-------------------------------------------|----------------------------------------|
|         | KING                PHARMACEUTICALS, INC. |
|    |                                 |                              |
|         | By:                             | /s/ Brian                Markison |
|         | Brian                Markison             |
|         | President                and CEO          |

|         |                            |                                 |
|--------------|---------------------------------|--------------------------------------|
|         | INYX,                INC.       |
|    |                       |                            |
|         | By:                   | /s/ Jack                Kachkar |
|         | Jack                Kachkar     |
|         | Chairman                and CEO |

**CONFIDENTIAL            TREATMENT**

----

**EXHIBIT        A**

**TECHNOLOGY        TRANSFER AGREEMENT**

**CONFIDENTIAL            TREATMENT**

----

**EXHIBIT        B**

**MANUFACTURING        AND SUPPLY AGREEMENT**

**CONFIDENTIAL            TREATMENT**

----

**EXHIBIT        C**

**MARKETING        AND PROMOTION AGREEMENT**

**CONFIDENTIAL            TREATMENT**

----

**EXHIBIT        D**

**DEVELOPMENT        AGREEMENT**

**CONFIDENTIAL            TREATMENT**

----

**EXHIBIT        E**

**QUALITY        AGREEMENT**

**CONFIDENTIAL            TREATMENT**

----